Is Wall Street Bullish or Bearish on STERIS Stock?

Core Viewpoint - STERIS plc is a significant player in the infection prevention market, with a market cap of $24.6 billion, providing a wide range of products and services to healthcare sectors globally [1] Financial Performance - STERIS reported Q3 2026 revenue of $1.5 billion, exceeding expectations, but shares fell 7.7% the following day due to a decline in gross margin and EBIT margin, alongside management's warning of a $55 million tariff impact and a potential slowdown in the second half of the fiscal year [5] - For the fiscal year ending in March 2026, analysts project adjusted EPS growth of 10.7% year-over-year to $10.21, with a history of surpassing consensus estimates in the last four quarters [6] Stock Performance - Over the past 52 weeks, STERIS shares have returned 13.5%, outperforming the S&P 500 Index's 11.7% gain and the State Street Health Care Select Sector SPDR ETF's 7.4% increase [2][3] - Despite a year-to-date decline, the stock remains rated as a "Moderate Buy" by analysts, with six "Strong Buy" ratings and three "Holds" [6] Analyst Ratings and Price Targets - Piper Sandler analyst Jason Bednar has reiterated a "Buy" rating on STERIS with a price target of $300, indicating a potential upside of 19.4% from the current price [7]